TARIS Biomedical, Inc.

TARIS™ Initiates Phase 2 Clinical Study with LiRIS® in Interstitial Cystitis Patients

TARIS™ Initiates Phase 2 Clinical Study with LiRIS® in Interstitial Cystitis Patients

November 30, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)-- TARIS Biomedical, Inc., a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 2 clinical study with its novel product candidate, LiRIS®, in patients with Interstitial Cystitis. LiRIS® is designed to continuously deliver lidocaine over an extended period directly to the bladder to relieve symptoms associated with Interstitial Cystitis, such as bladder pain and voiding dysfunction.

Alvine Pharmaceuticals, Inc.

Alvine's ALV003 Named a Top 10 Inflammatory/Autoimmune Project to Watch by Windhover for a Rare Second Year

Alvine's ALV003 Named a Top 10 Inflammatory/Autoimmune Project to Watch by Windhover for a Rare Second Year

November 29, 2011

SAN CARLOS, Calif.--(BUSINESS WIRE)--Nov 29, 2011 - Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, announced today that the company's lead therapeutic product candidate for celiac disease, ALV003, has been selected by Windhover and its advisors as one of “The Top 10 Inflammatory/Autoimmune Projects to Watch in 2012.” This is the second year that ALV003 has been named to the Top 10 list.

Mascoma Corporation

Mascoma Awarded $80 Million from the DOE for Construction of Commercial-Scale Hardwood Cellulosic Ethanol Facility in Kinross, Michigan

Mascoma Awarded $80 Million from the DOE for Construction of Commercial-Scale Hardwood Cellulosic Ethanol Facility in Kinross, Michigan

December 14, 2011

Lebanon, New Hampshire – Mascoma Corporation, a renewable fuels company, announced today that it has signed a cooperative agreement with the U.S. Department of Energy (DOE) to assist in the design, construction and operation of a commercial-scale hardwood cellulosic ethanol facility in Kinross, Michigan. The cooperative agreement provides for up to $80 million in DOE funding, in addition to $20 million in funding previously awarded by the DOE related to research and development for this project.

Affinnova, Inc.

Affinnova Delivers a Shot of Innovation for Breathable Foods

Affinnova Delivers a Shot of Innovation for Breathable Foods

December 12, 2011

WALTHAM, Mass., Dec 12, 2011 -- Affinnova, Inc., the global leader in marketing innovation software and services, has helped energize the launch of Breathable Foods' revolutionary new airborne energy shot. When Breathable Foods -- a Cambridge, MA-based creator of inhalable nutrients and sensations -- prepared to introduce its new AeroShot Pure Energy product to the marketplace, the company turned to Affinnova for help in optimizing a product message that would resonate with consumers.

Mascoma Corporation

Mascoma and Valero Establish Joint Venture for Commercial-Scale Hardwood Cellulosic Ethanol Facility in Kinross, Michigan

Mascoma and Valero Establish Joint Venture for Commercial-Scale Hardwood Cellulosic Ethanol Facility in Kinross, Michigan

December 9, 2011

Lebanon, New Hampshire – Mascoma Corporation, a renewable fuels company, announced today that it has entered into definitive agreements with Valero Energy Corporation, the nation’s largest independent oil refiner and a leading ethanol producer, to develop and operate a first-of-its-kind 20 million gallon per year commercial-scale cellulosic ethanol facility in Kinross, Michigan.

Avedro, Inc.

Avedro Announces Its Second FDA Orphan Drug Designation for Corneal Cross-linking

Avedro Announces Its Second FDA Orphan Drug Designation for Corneal Cross-linking

December 7, 2011

Avedro, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s VibeX (riboflavin ophthalmic solution) for use with its KXL System (UVA irradiation) for Corneal Cross-linking to treat corneal ectasia following refractive surgery, such as Lasik and photorefractive keratectomy (PRK). Corneal ectasia is a rare outcome of refractive surgery but is a progressive condition that is difficult to manage. This is the company’s second orphan drug designation for VibeX.

Affinnova, Inc.

Affinnova to Continue Expansion in 2012

Affinnova to Continue Expansion in 2012

November 30, 2011

WALTHAM, MA, USA  – Due to increased demand, Affinnova, Inc., the global leader in marketing innovation software and services, will hire up to 70 new staff members in 2012. The announcement was made by Waleed Al-Atraqchi, president and chief executive officer of Affinnova.

BG Medicine, Inc.

BG Medicine, Inc. Announces Peer-Reviewed Publication on Galectin-3 and Development of Heart Failure After Acute Coronary Syndrome (ACS)

BG Medicine, Inc. Announces Peer-Reviewed Publication on Galectin-3 and Development of Heart Failure After Acute Coronary Syndrome (ACS)

November 30, 2011

WALTHAM, Mass., (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today the availability of the peer-reviewed publication of the first clinical study on the role of galectin-3 in heart failure development.

Testing vaccine to block nicotine

Testing vaccine to block nicotine

November 27, 2011

What if there was a shot that you could get in a doctor’s office to negate the pleasurable effects of smoking a cigarette? It would last six months or a year, and then you might need a booster shot to prevent a relapse. Would you get it or recommend it to a family member or colleague who smokes? Would you give it to a teenage son or daughter who started hanging around with friends who smoke?
 

CEO Corner: Hiring Veterans

CEO Corner: Hiring Veterans

November 20, 2011

(NECN) - President Obama calls for the hiring of more Veterans, who have a disproportionately high jobless rate. 

Two men who are already committed to doing just that. 

Tom Pincince is President and CEO of Digital Lumens and Jim Matheson is a former Navy Pilot turned General Partner at Flagship Ventures. They will discuss why their companies hire Veterans.
 

Please click on NECN logo to view video